A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy
Hui Yang,1– 3 Shaoxing Sun,1– 3 Zijie Mei,1– 3 Qingming Xiang,1– 3 Chunxu Yang,1– 3 Min Chen,1– 3 Conghua Xie,1– 3 Yunfeng Zhou,1– 3 Hui Qiu1– 3 1Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, People’s Republic of China; 2Hubei Key Laboratory of Tumor Bio...
Guardado en:
Autores principales: | Yang H, Sun S, Mei Z, Xiang Q, Yang C, Chen M, Xie C, Zhou Y, Qiu H |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5f2008c894c74e8cbecb12edaf85fc3f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Exosomal miR-136-5p Derived from Anlotinib-Resistant NSCLC Cells Confers Anlotinib Resistance in Non-Small Cell Lung Cancer Through Targeting PPP2R2A
por: Gu G, et al.
Publicado: (2021) -
Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma
por: YU Xuxu, et al.
Publicado: (2021) -
Novel Nanocrystal Injection of Insoluble Drug Anlotinib and Its Antitumor Effects on Hepatocellular Carcinoma
por: Mei Luo, et al.
Publicado: (2021) -
Effectiveness of anlotinib in patients with small‐cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study
por: Ying Liu, et al.
Publicado: (2021) -
Successful Treatment of an Elderly Patient With Combined Small Cell Lung Cancer Receiving Anlotinib: A Case Report
por: Yuying Gan, et al.
Publicado: (2021)